Alan Health Technologies Inc. dba Alan

Warning LetterOpen

United StatesIssued Feb 20, 2026Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations3

Issue DateFeb 20, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Alan Health Technologies Inc. dba Alan
Location: United States
FEI Number: N/A
Country: United States
Issue Date: February 20, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Alan Health Technologies Inc. was cited for misbranding compounded semaglutide and tirzepatide drug products by falsely representing that Alan was the compounder when it was not, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's website displayed product labels identifying "Alan" as the manufacturer, creating misleading claims about the source and identity of these compounded drugs. These false or misleading representations resulted in misbranded products being introduced into interstate commerce in violation of section 301(a) of the FDCA.

Alan Health Technologies Inc. dba Alan FDA Warning Letter, February 20, 2026